Publications

Clinical

Categories
Search
Clinical, ZW171
June 2, 2025
ASCO
Design of a First-in-Human Multicenter Open-Label Study of ZW171, a Mesothelin x CD3–Targeting Bispecific T Cell Engager, in Participants With Advanced Solid Tumors: ZWI-ZW171-101
Johnson et al.
Clinical
October 13, 2023
AACR-EORTC-NCI
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Oh et al.
Clinical
September 12, 2022
ESMO
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Jhaveri et al.